Ranking the Top 10 pharmaceutical Therapy Areas and Oncology Drugs by revenue, market share, and growth trends 2017-2025
The global pharmaceutical prescription drug sales expected to reach $1.3 trillion in 2025, growing at a CAGR of 5.0% from 2019-2025. Pfizer will be the leading prescription drug company in 2025, growing at 2.0% CAGR, with total sales of $52.3 billion, ahead of Novartis and Roche.
Top 10 Therapy Areas Market 2017-2025 (Sales, $billion)
Global market for top 10 pharmaceutical therapy areas is estimated for oncology, anti-diabetics, anti-rheumatics, vaccines, anti-viral, immunosuppressants, dermatology, bronchodilators, sensory organs, and anti-coagulants categories for the period 2017 to 2025. The therapy area growth rate (% CAGR) and forecast sales ($billion) have been estimated from period 2019 to 2025.
The top 10 therapy areas would be accounted for 48.6% share of the global prescription drugs market revenue, growing at a CAGR of 6.5%, reaching $630 billion in 2025.
- Oncology segment would be the leading therapy segment in 2025, with a 20.4% market share and sales reaching $263 billion over the forecast period, driven in large by the PD-1 inhibitors Keytruda and Opdivo, as well as Pfizer’s Ibrance and AstraZeneca’s Tagrisso.
- Anti-diabetics therapy segment is forecast to remain the second biggest therapy area with sales of $59.3 billion in 2025, with Novo Nordisk’s diabetes portfolio responsible for driving growth.
- Although with the smallest decline of 1% CAGR, the anti-rheumatic therapy area ranked among the top three global pharmaceutical therapy areas market, with the anticipated market size of $54.0 billion by 2025. The market growth during forecast period would be supported by the introduction of JAK inhibitors and delayed biosimilar competition to Enbrel and Humira in the United States.
- The antivirals therapy segment is characterized by shrinking addressable market and pricing constraints within the HCV therapeutics. However, the continued uptake and launch of novel HIV antivirals like Biktarvy are likely to stabilize the sales during the forecast period, with a CAGR of 1.4%, reaching $42.8 billion by 2025.
- The immunosuppressants space is anticipated to grow at the largest CAGR of 15.4% through 2025, driven by an increase in the incidence of chronic diseases and the use of immunotherapeutic agents in clinical development for other therapy areas. The segment growth would also be driven by sales of Sanofi’s Dupixent and Johnson & Johnson’s Stelara.
Top 10 Oncology Drugs Market 2017-2025 (Sales, $billion)
Global market for top 10 oncology drugs is estimated for Keytruda, Opdivo, Ibrance (palbociclib), Imbruvica (ibrutinib), Revlimid, Xtandi (enzalutamide), Herceptin, Avastin, Neulasta/Peglasta (pegfilgrastim), and Rituxan /MabThera (rituximab) for the period 2017 to 2025. The oncology drug growth rate (% CAGR) and forecast sales ($billion) have been estimated from period 2019 to 2025.
The leading oncology drugs segment is anticipated to grow at a CAGR of 10.8%, reaching $263 billion by 2025, with a market share of 20.4% of the global prescription drugs market.
Top 10 Oncology Drugs Market
- Merck’s Keytruda remains one of the key growth drivers through 2025, along with Opdivo, Ibrance, and Imbruvica. Keytruda set to be the top selling drug worldwide, growing at a highest CAGR of 14.2% to attain sales of $19.6 billion in 2025.
- BMS and Ono Pharmaceutical’s PD-1 inhibitor, Opdivo will secure its second position with sales of $12.7 billion in 2025, with a CAGR of 6.7% over the forecast period.
- Pfizer’s Cyclin-dependent kinase 4 (CDK4) inhibitor, Ibrance (palbociclib) and Abbvie’s Bruton’s tyrosine kinase (BTK) inhibitor, Imbruvica (ibrutinib) set to take the third and fourth spots in 2025, with sales of $10.4 and $10.2 billion, respectively.
- Roche Holding’s oncology portfolio is its largest therapeutic area and it will likely remain flat with revenues of around $27 billion over the next few years, as decline in sales expected for MabThera, Herceptin, and Avastin.
- MabThera/Rituxan has lost its marketing exclusivity, and it now faces biosimilar competition from the budding class of copycat, Celltrion and Teva’s Truxima. Similarly, Herceptin has lost the market exclusivity, and now faces biosimilar competition from Pfizer’s Trazimera. Avastin will lose market exclusivity in 2019, and lead to generic competition from Pfizer’s Zirabev, which is already approved in the Europe.
Source: EvaluatePharma, iHealthcareAnalyst, Inc.